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Objective: The objective of this study was to demonstrate how decision‐analytic
modelling can help to determine circumstances under which surgery may become
cost‐effective, using septoplasty as an example.
Design: We developed a decision‐analytic model comparing septoplasty to non‐surgi-
cal management for nasal obstruction in adults with a deviated septum. Based on the
estimated cost difference between both treatments, we calculated the minimal (a) gain
in quality‐adjusted life‐years, or (b) reduction in productivity losses needed for septo-
plasty to be cost‐effective. Input was derived from literature and publicly available data
sources. The time horizon of our model was one year, and the willingness‐to‐pay per
quality‐adjusted life‐year was €20 000, in accordance with current guidelines.
Results: The cost difference between septoplasty and non‐surgical management for
nasal obstruction due to a deviated nasal septum was €2227 per patient from a
healthcare perspective (including direct healthcare costs) and €3288 per patient
from an extended perspective (additionally including travel expenses and productiv-
ity losses due to poor health). In comparison with non‐surgical management, septo-
plasty needed to gain 0.11 to 0.16 QALYs or save 13 sick days for nasal
obstruction. The longer septoplasty's effect lasts, the more time it will have to com-
pensate its extra costs.
Conclusion: This study shows that the known cost difference between treatments
can be used as the starting point to determine beneficial effects needed for cost‐ef-
fectiveness of surgical interventions. The effect required by septoplasty from a
healthcare perspective seems potentially achievable, meaning that it would be useful
to perform an RCT assessing the actual benefits of septoplasty.
1 | INTRODUCTION
1.1 | Rationale
In the era of value‐based healthcare, it is becoming increasingly
important to obtain evidence that interventions provide outcomes
valued by patients and society. As both costs and demands for care
are rising, the growing strain on resources is a cause for concern in
healthcare policy and practice. More than ever, the benefits of inter-
ventions need to be carefully weighed against their costs, to justify
their use to society.1
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Randomised controlled trials (RCTs) are the gold standard to
assess the effectiveness of surgical interventions, but conducting
RCTs can be methodologically challenging, costly and time‐consum-
ing. Consequently, the number of surgical trials has been consistently
low over the past decades.2 As a result, surgical interventions may
be routinely applied in daily practice, while high‐quality evidence for
their effectiveness is lacking.
Septoplasty, that is surgical correction of the deviated nasal sep-
tum, is an illustrative example within ENT‐practice. Although septo-
plasty is a common treatment for nasal obstruction, current
literature on its effectiveness is scarce and inconclusive.3 The esti-
mated prevalence of a deviated septum ranges up to 80%, whereas
only a minority suffers from nasal obstruction. It has been ques-
tioned whether straightening the septum provides any benefit to
those patients, and if so, which patients benefit most.4 Professional
associations of ENT‐surgeons have called for further research, but
RCTs comparing septoplasty with non‐surgical management are still
unavailable.5,6
However, even when effectiveness data are lacking, data on the
costs of an intervention are often present. These can be used to
determine the circumstances under which surgery may become cost‐
effective, thereby indicating whether cost‐effectiveness is potentially
feasible and thus informing future trials. Such analyses may be per-
formed using a decision‐analytic model, in which available data are
synthesised to compare alternative strategies in terms of effects,
costs, or both.
1.2 | Objective
The objective of this study was to illustrate the value of decision‐an-
alytic modelling when RCTs are absent, by assessing the minimal
effects or societal savings needed for septoplasty to compensate its
extra costs in comparison with non‐surgical management for nasal
obstruction in adults with a deviated septum.
2 | MATERIALS AND METHODS
2.1 | Ethical considerations
This modelling study was based on existing evidence. No original
data were collected in human participants. Approval by the institu-
tional ethics committee was not required.
2.2 | Target population
The target population represents a fictional cohort of patients pass-
ing through the model. Our target population consisted of adults
with nasal obstruction due to a deviated nasal septum and an indica-
tion to have septoplasty performed. Following regular practice in the
Netherlands and most other Western European countries, the target
population was not limited to those with specific characteristics,
such as a pre‐defined level of disease severity or a history of medical
management. In Dutch medical practice, the indication for
septoplasty is based on an internal examination of the nose, which
demonstrates that the deviation obstructs the nasal airway, leading
to impaired nasal breathing.
2.3 | Setting and comparators
This decision‐analytic model applies to secondary or tertiary health-
care settings. In the primary healthcare setting, medical treatment is
the only option both for patients later indicated to undergo surgery
as well as for patients following a non‐surgical strategy. As a result,
there was no reason to assume a cost difference at this point and
the primary healthcare setting was thus excluded from the model.
After referral by a primary care physician, patients with nasal
obstruction are diagnosed with nasal septal deviation by the ENT‐
surgeon. Treatment may consist of septoplasty or non‐surgical man-
agement. As the rationale behind septoplasty is to reduce symptoms
of nasal obstruction rather than merely straightening the deviated
septum, non‐surgical management is an equally suited alternative
under current conditions of equipoise, which was confirmed by a
recent systematic review.3 Surgical and non‐surgical management
share the same target population (adults with nasal obstruction and
a deviated septum) and intended effect (relieve of nasal complaints),
and are considered suitable comparators.7
Non‐surgical management may consist of watchful waiting or
medical treatment. The decision tree comparing septoplasty to non‐
surgical management for nasal obstruction due to septal deviation is
shown in Figure 1.
2.4 | Study perspective
The cost analysis was primarily conducted from a healthcare per-
spective, which includes direct healthcare costs (eg, treatment and
follow‐up).8 Additionally, the perspective was extended by adding
travel expenses and productivity losses due to poor health to the
Keypoints
 Decision‐analytic modelling can help to determine cir-
cumstances under which surgical interventions may
become cost‐effective.
 The cost difference between septoplasty and non‐surgi-
cal management for nasal obstruction due to a deviated
nasal septum was €2227 per patient from a healthcare
perspective and €3288 per patient from an extended
perspective. As a result, septoplasty needed to gain 0.11
to 0.16 QALYs or save 13 sick days for nasal obstruction
to compensate its extra costs.
 The effect required by septoplasty from a healthcare per-
spective seems potentially achievable, meaning that it
would be useful to perform a randomised controlled trial
assessing the actual benefits of septoplasty.
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model. The extended perspective was used to assess societal savings
needed for cost‐effectiveness of septoplasty.
2.5 | Time horizon
The time horizon refers to the length of time covered by the model.
A relevant time horizon should reflect all costs and consequences
associated with each treatment strategy. The time horizon over
which costs were evaluated in our model was one year. Within this
year, relevant events that could contribute to the costs of each
treatment strategy were expected to have occurred (including the
treatment of any long‐term complications after septoplasty). As non‐
surgical management did not involve surgery for persistent com-
plaints, delayed septoplasty was not taken into account in the mod-
el's time horizon.
2.6 | Model input
The healthcare resources consumed and travel expenses or produc-
tivity losses incurred by each of the two treatment strategies are
described below.
2.6.1 | Septoplasty
Undergoing septoplasty requires: an intake at the ENT outpatient
clinic; pre‐anaesthetic assessment; surgery (as day‐case or overnight
procedure); and one or two follow‐up appointments. Medication is
not usually needed, apart from postoperative analgesics. As maxi-
mum pain is commonly experienced within the first 24 to 48 hours
after septoplasty, we assumed that patients would need mild anal-
gesics (that is acetaminophen) during the first two postoperative
days.9
Additional follow‐up is needed in case of short‐term adverse
events, that is, complications occurring within 6 weeks after septo-
plasty: nasal infection, epistaxis, septal haematoma, or adhesions.10
Furthermore, nasal infection or septal haematoma requires medica-
tion. Based on a meta‐analysis of studies on short‐term adverse
events after septoplasty, the risk of developing nasal infection or
septal haematoma was estimated to be 2%.11 It was assumed that
patients with nasal infection or septal haematoma would be treated
with oral antibiotics (that is amoxicillin‐clavulanate) during 1 week.
Additional healthcare resources are also consumed in case of
long‐term adverse events: severe adhesions, nasal septal perforation,
or saddle nose deformity.12 These complications occur typically
within the first year after surgery and may develop after a previously
uncomplicated recovery. Based on literature, the risk of developing
long‐term adverse events was estimated to be 1%.13,14 As the treat-
ment of long‐term complications consists of septal surgery, they
required the same healthcare resources as primary septoplasty: out-
patient consultation (intake and one or two follow‐up visits); pre‐
anaesthetic assessment; surgery (as day‐case or overnight proce-
dure); and mild analgesics (that is acetaminophen) during the first
two postoperative days.
Based on clinical experience, uncomplicated septoplasty was esti-
mated to incur travel expenses for five hospital visits: three appoint-
ments with the ENT‐surgeon, one appointment with the
anaesthesiologist, and one day of surgery. One additional visit was
added for the proportion of patients with short‐term complications,
and five additional visits for the proportion of patients with long‐
term adverse events.
According to literature and clinical experience, patients may take
one to two weeks of sick leave for postoperative recovery.15 Seven
days of absence from work were taken into account in calculating
productivity losses after uncomplicated septoplasty. Another seven
days were added in case of long‐term complications, which were
assumed to be treated surgically.
2.6.2 | Non‐surgical management
To be conservative towards the potential cost‐effectiveness of sep-
toplasty, we assumed that all patients following a non‐surgical strat-
egy would receive nasal medication. Thus, undergoing non‐surgical
management involves outpatient consultation and intranasal corti-
costeroids, as meta‐analyses have shown that these are more effec-
tive than antihistamines in the treatment of nasal obstruction.16
Intranasal corticosteroids have a limited risk of complications. Short‐
F IGURE 1 Decision tree of septoplasty versus non‐surgical management
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term adverse events are usually mild, such as mucosal irritation or
self‐limiting epistaxis.17 The main long‐term adverse event is nasal
septal perforation, which occurs very rarely and is associated with
improper spray application.18 Therefore, complications after non‐sur-
gical management were not included in the decision‐analytic model.
It was estimated that non‐surgical management would incur tra-
vel expenses for three hospital visits (intake and follow‐up at the
ENT outpatient clinic).
Following a non‐surgical strategy may entail productivity losses
due to persistent complaints of nasal obstruction despite medical
treatment. As no data are available on sick days of patients undergo-
ing non‐surgical management, we calculated the reduction in produc-
tivity losses needed for septoplasty to compensate its extra costs.
2.7 | Data sources
In the Netherlands, fixed revenues for healthcare resources are
derived from a case‐mix system, based on “diagnosis treatment com-
binations” (DBCs). The fixed revenue for septal surgery (including
outpatient consultation) and the fixed revenue for outpatient consul-
tation only (when following non‐surgical management) were pub-
lished by the Dutch Healthcare Authority (Nederlandse
Zorgautoriteit, NZa) on www.opendisdata.nl.
Nasal medication costs were calculated by averaging costs of
eight frequently prescribed local steroids (both generic and brand‐
name). Medication costs were provided by the Dutch Healthcare
Authority on www.farmacotherapeutischkompas.nl. All healthcare
costs were based on the 2017 price level.
Travel expenses for each hospital visit were composed of motor
vehicle expenses and parking costs. Standard rates were derived
from the Dutch guideline for costing research and based on the
2017 price level.8
To calculate productivity losses, the proportion of employed per-
sons and the average working hours per week in 2016 were
obtained from Statistics Netherlands (Centraal Bureau voor de Sta-
tistiek, CBS). Costs for one hour of lost work were derived from the
Dutch guideline for costing research and based on the 2017 price
level.8
2.8 | Analyses
We determined the total costs for each of the two treatment strate-
gies and assessed the minimal effects or societal savings needed for
septoplasty to compensate its extra costs in comparison with non‐
surgical management.
The required effect was expressed as a gain in quality‐adjusted
life‐years (QALYs). QALYs are the product of quantity (duration) and
quality of health (expressed in a utility score ranging from 0 to 1, with
0 representing death and 1 representing perfect health). One QALY
thus equals one year spent in perfect health. The QALY‐gain yielded
by an intervention is weighed against its cost using the willingness‐to‐
pay (WTP) per QALY as a reference. A WTP of €20 000 per QALY
means that society is willing to pay on average €20 000 per patient
for an intervention, if the patient will spend one year in perfect health
due to that intervention. The Dutch WTP ranges from €20 000 to
€80 000 per QALY, depending on the burden of disease.8 For this
modelling study, we adhered to a WTP of €20 000 per QALY.
The societal savings needed for septoplasty to compensate its
extra costs were expressed as reduced productivity losses, that is a
decrease in sick days for nasal obstruction due to having undergone
septoplasty. Sick days were calculated based on an average of 36
working hours per week.
The analyses were performed using Microsoft Excel 2016 (Micro-
soft Corporation, Redmond, WA, USA).
3 | RESULTS
3.1 | Model input
Input parameters from a healthcare perspective (including direct
healthcare costs) and from an extended perspective (also including
travel expenses and productivity losses due to poor health) are
shown in Tables 1 and 2, respectively.
3.2 | Healthcare perspective
Mean total costs per patient undergoing septoplasty were €2407.
Mean total costs per patient following a non‐surgical strategy were
€180. Consequently, the difference in costs between both treatment
strategies was €2227. Given a WTP of €20 000 per QALY, septo-
plasty needed to gain at least 0.11 QALYs to be cost‐effective, that
is 40 days spent in perfect health. A durable effect is favourable to
septoplasty: the required utility‐gain per unit of time decreases as
the effect duration increases.
3.3 | Extended perspective
Taking travel expenses and productivity losses due to postoperative
recovery into account, mean total costs per patient were €3485 for
septoplasty and €197 for non‐surgical management. The cost differ-
ence between treatments thus became €3288. Based on a WTP of
€20 000 per QALY, septoplasty needed to gain at least 0.16 QALYs
to be cost‐effective, that is 58 days spent in perfect health. Assuming
no difference in QALYs, septoplasty could also be cost‐effective by
preventing at least 13 sick days, that is 95 hours of work that would
otherwise have been lost due to nasal obstruction and accompanying
complaints, such as sleep disturbances or (recurrent) infections.
3.4 | Uncertainty
To examine the impact of uncertainty in the model input, we chan-
ged the value of one specific input parameter per time and then
repeated our analyses.
We started with recalculating outcomes using the upper range
limit of medication costs, to be conservative towards septoplasty.
The cost difference decreased to €2194 from a healthcare
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perspective and €3255 from the extended perspective. However, the
required effects or societal savings remained unchanged.
Next, we varied the sick leave taken to recover from septoplasty
and repeated our analyses from the extended perspective. If the
duration of sick leave decreased from 7 to 5 working days, the cost
difference between treatments decreased to €2988. The required
QALY‐gain became 0.15, that is 55 days spent in perfect health. The
number of sick days for nasal obstruction to be prevented by septo-
plasty dropped to 12, that is 86 hours of work that would otherwise
have been lost.
Nonetheless, if the duration of sick leave increased from 7 to 10
working days, the cost difference between treatments increased to
€3737. Accordingly, the required QALY‐gain became 0.19, that is
96 days spent in perfect health. The number of sick days to be pre-
vented by septoplasty became 15, that is 107 hours of work other-
wise lost because of nasal obstruction.
Furthermore, we subsequently subtracted and added 10% of
each fixed revenue as a measure of sensitivity. After subtracting
10%, the cost difference decreased to €1998 from a healthcare per-
spective and €3059 from an extended perspective, leading to a 0.01
decrease in the required QALY‐gain, which became 0.10 and 0.15,
respectively. The number of sick days to be prevented by septo-
plasty decreased to 12 instead of 13. Adding 10% had the opposite
effect: the cost difference increased to €2454 from a healthcare
TABLE 1 Input parameters of the decision‐analytic model comparing septoplasty to non‐surgical management from a healthcare perspective,
including direct healthcare costs
Input parameter Value Range Source
Septoplasty
Fixed revenue for septoplastya €2335.00 NA DBC Information System (DIS) 2017—Dutch Healthcare Authority
Two days of postoperative analgesics €1.38 €0.24‐€2.52 Pharmacy Purchase Price Index 2017—Dutch Healthcare Authority
Seven days of postoperative antibiotics
for nasal infectionb
€7.77 €2.10‐€13.44 Pharmacy Purchase Price Index 2017—Dutch Healthcare Authority
Seven days of postoperative antibiotics
for septal haematomab
€7.77 €2.10‐€13.44 Pharmacy Purchase Price Index 2017—Dutch Healthcare Authority
Fixed revenue for severe adhesionsa,c €2335.00 NA DBC Information System (DIS) 2017—Dutch Healthcare Authority
Fixed revenue for nasal septal
perforationa,c
€2335.00 NA DBC Information System (DIS) 2017—Dutch Healthcare Authority
Fixed revenue for saddle nose
deformitya,c
€2335.00 NA DBC Information System (DIS) 2017—Dutch Healthcare Authority
Non‐surgical management
Fixed revenue for outpatient
consultation
€125.00 NA DBC Information System (DIS) 2017—Dutch Healthcare Authority
One year of intranasal corticosteroids €55.32 €21.57‐€89.06 Pharmacy Purchase Price Index 2017—Dutch Healthcare Authority
aFixed revenue includes: outpatient consultation (pre‐ and postoperative visits); pre‐anaesthesia evaluation; surgery (day‐case or overnight).
bEstimated proportion of patients affected: 2%.11
cEstimated proportion of patients affected: 1%.13,14
TABLE 2 Input parameters of the decision‐analytic model comparing septoplasty to non‐surgical management from an extended perspective,
including direct healthcare costs, travel expenses and productivity losses due to poor health
Input parameter Value Range Source
Average distance to the hospital (one‐way) 7.0 km NA Dutch guideline for costing research 2017
Average motor vehicle expenses per kilometre €0.19 NA Dutch guideline for costing research 2017
Average parking costs per hospital visit €3.00 NA Dutch guideline for costing research 2017
Total travel expenses per hospital visita €5.66 NA Dutch guideline for costing research 2017
Proportion of employed persons 65.8% ♀: 60.9%
♂: 70.8%
Statistics Netherlands 2016
Average hours worked per weekb 32.2 h ♀: 26 h
♂: 36 h
Statistics Netherlands 2016
Average costs per hour of lost work €35.00 NA Dutch guideline for costing research 2017
Total societal costs per sick dayc €148.27 NA Statistics Netherlands 2016 and Dutch guideline for costing research 2017
aTotal number of hospital visits per treatment strategy: 5 for uncomplicated septoplasty; 6 for septoplasty with short‐term complications; 10 for septo-
plasty with long‐term complications; 3 for non‐surgical management.
bWeighted average based on the contribution of men (61.9%) and women (38.1%) to the total number of hours worked.
cTotal number of sick days: 7 for uncomplicated septoplasty and septoplasty with short‐term complications; 14 for septoplasty with long‐term complica-
tions.
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perspective and €3515 from an extended perspective, leading to an
increase of 0.01 in the required QALY‐gain (for both perspectives)
and an increase of 1 day in the number of sick days to be prevented
by septoplasty.
Finally, we tested whether the model was sensitive to a reduc-
tion in the number of hospital visits required by septoplasty, but this
did not change the outcome. Also a reduction in the odds of devel-
oping long‐term adverse events did not alter the results.
A graphical overview of the sensitivity analyses from an
extended perspective is provided in Figure 2.
4 | DISCUSSION
4.1 | Key findings
Our decision‐analytic model showed that the cost difference between
septoplasty and non‐surgical management for nasal obstruction due
to a deviated nasal septum was €2227 per patient from a healthcare
perspective and €3288 per patient from the extended perspective.
Given a WTP of €20 000 per QALY, the minimal QALY‐gain required
for cost‐effectiveness of septoplasty was 0.11 (that is 40 days spent
in perfect health) and 0.16 (that is 58 days spent in perfect health),
respectively. Septoplasty would also be cost‐effective by preventing
at least 13 sick days because of nasal obstruction. Regarding the
extended perspective, uncertainty in the duration of sick leave for
postoperative recovery had considerable impact on the required
QALY‐gain (ranging from 0.15 to 0.19, that is 55 to 96 days spent in
perfect health) and societal savings (ranging from 12 to 15 sick days
for nasal obstruction to be prevented by septoplasty).
4.2 | Comparison with the literature
The required QALY‐gain was evaluated in the light of benefits from
other surgical interventions, see Table 3. We searched the literature
for RCTs comparing elective minor surgery to non‐surgical strategies
in terms of quality‐adjusted life‐years as measured with the EQ‐5D
in adults. This type of RCTs was found to be especially common in
the field of orthopaedics. We decided to include these in Table 3, as
the interventions were elective and minor like septoplasty, and the
QALY as a generic measure of disease burden particularly facilitates
a trans‐disciplinary view. Large differences in effect were found,
ranging from 0.01 to 0.13 QALYs, that is 4 to 48 days spent in per-
fect health. Overall, the QALY‐gain required by septoplasty from a
healthcare perspective seems potentially achievable. Our model,
however, does not provide insight in the effect of septal surgery in
daily practice. To determine the effectiveness of septoplasty, a prag-
matic RCT is needed.
4.3 | Strengths and limitations
The major strength of this modelling study is that we have
approached the current evidence gap surrounding septoplasty from a
new angle. The known difference in costs between septoplasty and
non‐surgical management was the starting point to determine the
beneficial effects required for cost‐effectiveness of septoplasty,
using a decision‐analytic model. Our study shows that decision‐ana-
lytic modelling can help to determine conditions for cost‐effective-
ness, even when RCTs are absent. Furthermore, this study is
reported in accordance with the Consolidated Health Economic Eval-
uation Reporting Standards (CHEERS).19 The completed CHEERS
checklist is provided in Appendix 1.
Nonetheless, several limitations should also be discussed. First,
our input parameter values were not prospectively measured.
Instead, the model input was composed of fixed revenues and stan-
dard rates, which included all relevant component costs. This was
the best available alternative (given the status of current evidence)
and an acknowledged substitute to prospective data.8
Second, since all costs were based on Dutch healthcare prices,
small differences with other countries may exist. It is expected, how-
ever, that the overall trend will be similar. Furthermore, the detailed
presentation of this model provides the opportunity to repeat our
analyses with values specific to other situations and countries. To
demonstrate the value of decision‐analytic modelling in a clinical set-
ting, we developed a model for septoplasty from a Dutch perspec-
tive; but the potential application of this methodology is certainly
not limited to a specific field or region.
Third, the time horizon of our model was one year, during which
all relevant expenses were expected to have occurred. For modelling
F IGURE 2 Tornado plot of sensitivity
analyses from an extended perspective
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studies with trial data, a longer horizon may be appropriate. In our
case, however, both the magnitude and the duration of septoplasty's
effect remain to be assessed. In general, a durable effect is favour-
able to septoplasty: the longer the effect lasts, the more time septo-
plasty will have to compensate its extra costs, that is the lower the
utility‐gain per unit of time needs to be.
4.4 | Clinical implications
As septoplasty is routinely performed in ENT‐practice, the total soci-
etal costs incurred by this treatment are significant. Consequently,
evaluating the cost‐effectiveness of septal surgery is of high rele-
vance to many patients, healthcare providers, and policy makers,
especially in the current era of value‐based healthcare. The method-
ology presented in this study can be applied to other surgical inter-
ventions which, like septoplasty, are commonly performed while
high‐quality evidence is lacking. Determining the health gain required
to compensate the extra costs of surgery helps to inform future tri-
als, whose effectiveness data can be entered in the model when
they become available. With data from a pragmatic trial, the cost‐ef-
fectiveness of septoplasty can also be assessed in a population of
patients undergoing a mix of medical and surgical therapy, as often
seen in clinical practice. Our results indicate that an RCT on the
effectiveness of septoplasty is by no means superfluous: as septal
surgery has the potential to be cost‐effective, further research is
needed to assess the effectiveness of septoplasty in clinical practice.
5 | CONCLUSION
This study shows that a decision‐analytic model can be used to
determine under which circumstances surgery may become cost‐ef-
fective, even when RCTs are absent. In comparison with non‐surgical
management, septoplasty needed to gain 0.11 to 0.16 QALYs (that
is 40 to 58 days spent in perfect health) or save 13 sick days for
nasal obstruction to compensate its extra costs. This seems poten-
tially achievable. A future RCT is required to determine septoplasty's
effectiveness.
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APPENDIX
COMPLETED CHEERS CHECKLIST: ITEMS TO INCLUDE WHEN REPORTING ECONOMIC
EVALUATIONS OF HEALTH INTERVENTION
Section/item
Item
No Recommendation
Reported on
page No/line
No
Title and abstract
Title 1 Identify the study as an economic evaluation or use more specific terms such as
“cost‐effectiveness analysis,” and describe the interventions compared.
P. 1/L. 1,2
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods
(including study design and inputs), results (including base case and uncertainty
analyses) and conclusions.
P. 3,4/L. 40‐71
Introduction
Background and objectives 3 Provide an explicit statement of the broader context for the study. P. 5,6/L. 78‐116
Present the study question and its relevance for health policy or practice decisions. P. 5,6/L. 78‐116
Methods
(Continues)
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TABLE (Continued)
Section/item
Item
No Recommendation
Reported on
page No/line
No
Target population and subgroups 4 Describe characteristics of the base case population and subgroups analysed,
including why they were chosen.
P. 7/L. 123‐129
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made. P. 7/L. 131‐140
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated. P. 8/L. 142‐147
Comparators 7 Describe the interventions or strategies being compared and state why they were
chosen.
P. 7/L. 131‐140
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated
and say why appropriate.
P. 8/L. 149‐154
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why
appropriate.
NA
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in the evaluation
and their relevance for the type of analysis performed.
P. 11,12/L. 232‐
251
Measurement of effectiveness 11a Single study‐based estimates: Describe fully the design features of the single
effectiveness study and why the single study was a sufficient source of clinical
effectiveness data.
NA
11b Synthesis‐based estimates: Describe fully the methods used for identification of
included studies and synthesis of clinical effectiveness data.
NA
Measurement and valuation of
preference based outcomes
12 If applicable, describe the population and methods used to elicit preferences for
outcomes.
NA
Estimating resources and costs 13a Single study‐based economic evaluation: Describe approaches used to estimate
resource use associated with the alternative interventions. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs.
NA
13b Model‐based economic evaluation: Describe approaches and data sources used to
estimate resource use associated with model health states. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs.
P. 8‐10/L. 160‐
211
Currency, price date, and
conversion
14 Report the dates of the estimated resource quantities and unit costs. Describe
methods for adjusting estimated unit costs to the year of reported costs if
necessary. Describe methods for converting costs into a common currency base
and the exchange rate.
P. 10,11/L. 213‐
230
Choice of model 15 Describe and give reasons for the specific type of decision‐analytical model used.
Providing a figure to show model structure is strongly recommended.
P. 7/L. 131‐140
Assumptions 16 Describe all structural or other assumptions underpinning the decision‐analytical
model.
P. 7‐12/L. 117‐
251
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include
methods for dealing with skewed, missing or censored data; extrapolation
methods; methods for pooling data; approaches to validate or make adjustments
(such as half cycle corrections) to a model; and methods for handling population
heterogeneity and uncertainty.
P. 11,12/L. 232‐
251
Results
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all
parameters. Report reasons or sources for distributions used to represent
uncertainty where appropriate. Providing a table to show the input values is
strongly recommended.
P. 13/L. 254‐
257
Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of estimated
costs and outcomes of interest, as well as mean differences between the
comparator groups. If applicable, report incremental cost‐effectiveness ratios.
P. 13/L. 259‐
273
(Continues)
APPENDIX 1 (Continued)
VAN EGMOND ET AL. | 61
TABLE (Continued)
Section/item
Item
No Recommendation
Reported on
page No/line
No
Characterising uncertainty 20a Single study‐based economic evaluation: Describe the effects of sampling uncertainty
for the estimated incremental cost and incremental effectiveness parameters,
together with the impact of methodological assumptions (such as discount rate,
study perspective).
NA
20b Model‐based economic evaluation: Describe the effects on the results of uncertainty
for all input parameters, and uncertainty related to the structure of the model and
assumptions.
P. 13,14/L. 275‐
292
Characterising heterogeneity 21 If applicable, report differences in costs, outcomes, or cost‐effectiveness that can
be explained by variations between subgroups of patients with different baseline
characteristics or other observed variability in effects that are not reducible by
more information.
NA
Discussion
Study findings, limitations,
generalisability, and current
knowledge
22 Summarise key study findings and describe how they support the conclusions
reached. Discuss limitations and the generalisability of the findings and how the
findings fit with current knowledge.
P. 15‐17/L.
293‐364
Other
Source of funding 23 Describe how the study was funded and the role of the funder in the identification,
design, conduct and reporting of the analysis. Describe other non‐monetary
sources of support.
P. 2/L. 34‐39
Conflict of interests 24 Describe any potential for conflict of interest of study contributors in accordance
with journal policy. In the absence of a journal policy, we recommend authors
comply with International Committee of Medical Journal Editors
recommendations.
P. 18/L. 365‐
367
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist.
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